论文部分内容阅读
在心肌局部缺血和心肌梗塞的治疗和预防工作中,需要鉴别心肌损伤的性质和程度。用放射性药物进行体外显像,可提供重要依据。检查心肌病变的显像方法有二种:一为冷区显像(Cold spot imaging),即应用正常心肌组织摄取放射性药物,而病变心肌组织不摄取或很少摄取,形成一个放射性“冷”区,间接显示病变;一为热区显像(Hot spot imaging),即运用亲病变心肌的放射性药物,在病变组织形成一放射性“热”区,直接显像。放射性药物在动物或人体内的靶器官与非靶器官浓集比率(T/NT)、显像特性、药物在体内留存时间及血清除率、对机体的辐射剂量等,都是评价放射性药物的主要依据。
In the treatment and prevention of myocardial ischemia and myocardial infarction, there is a need to identify the nature and extent of myocardial damage. In vitro imaging with radiopharmaceuticals provides an important basis. There are two ways to check for myocardial lesions: one is Cold spot imaging, where normal myocardial tissue is used to take up a radiopharmaceutical, and the diseased myocardium is not ingested or seldom ingested to form a radioactive “cold” zone , Indirectly shows the lesion; one for hot spot imaging (Hot spot imaging), that is, the use of the pro-myocardium of the radiopharmaceutical, in the lesion formation of a radioactive “hot” area, direct imaging. The target organ to non-target organ concentration ratio (T / NT) of radiopharmaceutical in animal or human body, imaging characteristics, drug retention time in vivo and serum clearance rate, radiation dose on the body, etc., are evaluated radiopharmaceutical mostly according.